These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 19732054

  • 1. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ.
    Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
    [Abstract] [Full Text] [Related]

  • 2. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Khan A, Hangartner T, Weinreb NJ, Taylor JS, Mistry PK.
    J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
    [Abstract] [Full Text] [Related]

  • 3. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.
    Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
    [Abstract] [Full Text] [Related]

  • 4. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
    Basiri M, Ghaffari ME, Ruan J, Murugesan V, Kleytman N, Belinsky G, Akhavan A, Lischuk A, Guo L, Klinger K, Mistry PK.
    Elife; 2023 May 30; 12():. PubMed ID: 37249220
    [Abstract] [Full Text] [Related]

  • 5. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 30; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 6. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
    Deegan P, Khan A, Camelo JS, Batista JL, Weinreb N.
    Orphanet J Rare Dis; 2021 Feb 18; 16(1):92. PubMed ID: 33602299
    [Abstract] [Full Text] [Related]

  • 7. Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1.
    Lollert A, Laudemann K, Mengel E, Hoffmann C, Moos L, Reinke J, Brixius-Huth M, Hennermann JB, Düber C, Staatz G.
    Klin Padiatr; 2019 Mar 18; 231(2):52-59. PubMed ID: 30481833
    [Abstract] [Full Text] [Related]

  • 8. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
    Potnis KC, Flueckinger LB, Ha CI, Upadia J, Frush DP, Kishnani PS.
    Mol Genet Metab; 2019 Feb 18; 126(2):157-161. PubMed ID: 30448006
    [Abstract] [Full Text] [Related]

  • 9. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 18; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 10. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Sevittz H, Laher F, Varughese ST, Nel M, McMaster A, Jacobson BF.
    S Afr Med J; 2022 Feb 02; 112(1):13518. PubMed ID: 35140000
    [Abstract] [Full Text] [Related]

  • 11. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 02; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 12. Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1.
    Cerón-Rodríguez M, Barajas-Colón E, Ramírez-Devars L, Gutiérrez-Camacho C, Salgado-Loza JL.
    Mol Genet Genomic Med; 2018 Jan 02; 6(1):27-34. PubMed ID: 29471591
    [Abstract] [Full Text] [Related]

  • 13. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Jan 02; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 14. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.
    Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, Al Khzouz C, Bucerzan S, Naşcu I, Zimmermann T, Leucuţa D, Weber MM.
    J Inherit Metab Dis; 2013 May 02; 36(3):555-63. PubMed ID: 22976766
    [Abstract] [Full Text] [Related]

  • 15. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):66-72. PubMed ID: 21112800
    [Abstract] [Full Text] [Related]

  • 16. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.
    Drelichman G, Fernández Escobar N, Basack N, Aversa L, Larroude MS, Aguilar G, Szlago M, Schenone A, Fynn A, Cuello MF, Aznar M, Fernández R, Ruiz A, Reichel P, Guelbert N, Robledo H, Watman N, Bolesina M, Elena G, Veber SE, Pujal G, Galván G, Chain JJ, Arizo A, Bietti J, Bar D, Dragosky M, Marquez M, Feldman L, Muller K, Zirone S, Buchovsky G, Lanza V, Sanabria A, Fernández I, Jaureguiberry R, Contte M, Barbieri María A, Maro A, Zárate G, Fernández G, Rapetti MC, Donato H, Degano A, Kantor G, Albina R, Á Lvarez Bollea M, Brun M, Bacciedoni V, Del Río F, Soberón B, Boido N, Schweri M, Borchichi S, Welsh V, Corrales M, Cedola A, Carvani A, Diez B, Richard L, Baduel C, Nuñez G, Colimodio R, Barazzutti L, Medici H, Meschengieser S, Damiani G, Nucifora M, Girardi B, Gómez S, Papucci M, Verón D, Quiroga L, Carro G, De Ambrosio P, Ferro J, Pujol M, Castella CC, Franco L, Nisnovich G, Veloso M, Pacheco I, Savarino M, Marino A, Saavedra JL.
    Am J Hematol; 2016 Oct 15; 91(10):E448-53. PubMed ID: 27420181
    [Abstract] [Full Text] [Related]

  • 17. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 15; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 18. [Gaucher disease with multiple bone necrosis treated by enzyme replacement therapy and pamidronate].
    Abe M, Minoguchi M, Jinbo J, Kikuchi Y, Chiba A, Shibata Y, Kogo Y.
    Nihon Naika Gakkai Zasshi; 2004 Nov 10; 93(11):2421-3. PubMed ID: 15624481
    [No Abstract] [Full Text] [Related]

  • 19. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.
    Andrade-Campos M, Alfonso P, Irun P, Armstrong J, Calvo C, Dalmau J, Domingo MR, Barbera JL, Cano H, Fernandez-Galán MA, Franco R, Gracia I, Gracia-Antequera M, Ibañez A, Lendinez F, Madruga M, Martin-Hernández E, O'Callaghan MDM, Del Soto AP, Del Prado YR, Sancho-Val I, Sanjurjo P, Pocovi M, Giraldo P.
    Orphanet J Rare Dis; 2017 May 03; 12(1):84. PubMed ID: 28468677
    [Abstract] [Full Text] [Related]

  • 20. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.
    Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, Hughes D, Wraith JE, Cox TM.
    Medicine (Baltimore); 2011 Jan 03; 90(1):52-60. PubMed ID: 21200186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.